Quarterly Activities Report For the period ending 30 June 2022
New ResAppDx customer agreement with Dartford and Gravesham NHS Trust (UK)
One-year extension to Medgate licence agreement with expansion into Germany in CY2023
Validation study of COVID-19 algorithm showed 84% sensitivity and 58% specificity, substantially lower than pilot study
US FDA 510(k) clearance for SleepCheckRx
Customer receipts for the quarter, including $4,056,000 received from Pfizer under the research and development licence agreement, increased to $4,207,000 (Q3: $178,000)
Quarterly Activities Report For the period ending 30 June 2022...
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)